Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation
Francisco M. Marty(Brigham and Women's Hospital), Joseph H. Antin(Dana-Farber Cancer Institute), Corey Cutler(Harvard University), Colleen Lowry(Brigham and Women's Hospital), Karen Fiumara, Bonnie Campbell(Dana-Farber Cancer Institute), Lindsey R. Baden(Brigham and Women's Hospital)
Cited by 112
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k